Want to see HK:0474 full AI Analyst Report?
Top Page
Aceso Life Science Group Limited
(0474)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$0.14
▲(16.67% Upside)
Action:Reiterated
Date:08/29/26
The score is primarily held back by weak and volatile financial performance, including heavy leverage and inconsistent operating results despite a recent rebound. Technicals are supportive given the uptrend and positive MACD, but overbought readings add near-term risk. Valuation helps with a low P/E, though the lack of dividend data limits additional support.
Positive Factors
Balance-sheet repair
Lower debt and higher equity in 2026 represent a meaningful improvement from the prior year’s exceptionally thin equity base. This repair can reduce balance-sheet strain and provide somewhat greater financial flexibility, although leverage remains elevated.
Negative Factors
Sharp revenue contraction
A steep annual revenue decline following a strong prior year signals an unstable top-line trajectory and makes future earnings harder to forecast. Persistent revenue volatility can weaken operating leverage, reduce reinvestment capacity, and undermine the durability of the recent profit rebound.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet repair
Lower debt and higher equity in 2026 represent a meaningful improvement from the prior year’s exceptionally thin equity base. This repair can reduce balance-sheet strain and provide somewhat greater financial flexibility, although leverage remains elevated.
Read all positive factors
Aceso Life Science Group Limited (0474) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.26B
Dividend Yield1.2%
Average Volume (3M)1.45M
Price to Earnings (P/E)3.0
Beta (1Y)0.58
Revenue Growth-57.48%
EPS GrowthN/A
CountryHK
Employees28
SectorIndustrials
Sector Strength72
IndustryRental & Leasing Services
Share Statistics
EPS (TTM)0.05
Shares Outstanding8,858,127,000
10 Day Avg. Volume756,111
30 Day Avg. Volume1,448,773
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.53
Price to Sales (P/S)10.91
P/FCF Ratio34.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Aceso Life Science Group Limited Business Overview & Revenue Model
Company Description
Aceso Life Science Group Limited, an investment holding company, engages in the financial services, property leasing and development, and construction machinery businesses in Hong Kong and the United Kingdom. It operates through rental and sale of...
Aceso Life Science Group Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
28
Negative
Cash Flow
41
Neutral
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 64.00M | 195.00M | 11.00M | 312.00M | 315.00M |
| Gross Profit | 54.00M | 90.00M | -100.00M | 141.00M | 162.00M |
| EBITDA | -297.00M | -860.00M | -220.00M | -21.00M | -359.00M |
| Net Income | 338.00M | -895.00M | -462.00M | -264.00M | -370.00M |
Balance Sheet | |||||
| Total Assets | 1.79B | 3.24B | 4.79B | 6.30B | 6.26B |
| Cash, Cash Equivalents and Short-Term Investments | 345.00M | 207.00M | 466.00M | 602.00M | 717.00M |
| Total Debt | 1.19B | 2.30B | 2.74B | 2.34B | 3.01B |
| Total Liabilities | 1.33B | 2.50B | 2.97B | 3.73B | 3.44B |
| Stockholders Equity | 457.00M | 12.00M | 921.00M | 1.55B | 2.00B |
Cash Flow | |||||
| Free Cash Flow | 20.00M | 15.00M | -48.00M | 175.00M | 259.00M |
| Operating Cash Flow | 20.00M | 17.00M | -37.00M | 222.00M | 316.00M |
| Investing Cash Flow | 674.00M | 337.00M | 472.00M | -120.00M | -441.00M |
| Financing Cash Flow | -681.00M | -587.00M | 117.00M | -98.00M | 126.00M |
Aceso Life Science Group Limited Technical Analysis
Neutral
0.12
Price Trends
0.14
Positive
0.12
Positive
0.12
Positive
Market Momentum
>-0.01
Positive
44.33
Neutral
64.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0474, the sentiment is Neutral. The current price of 0.12 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.14, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.33 is Neutral, neither overbought nor oversold. The STOCH value of 64.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:0474.
Aceso Life Science Group Limited Peers Comparison
UnderperformOutperform
Sector (63)
HK:0474
Aceso Life Science Group Limited
0.14
0.08
136.67%
HK:2327
Meilleure Health International Industry Group Limited
0.21
-0.08
-28.13%
Aceso Life Science Group Limited Corporate Events
Aceso Life Science Scraps Major Share Subscription Deal, Cites Unmet Conditions
Sep 17, 2026
Aceso Life Science Group Limited has terminated a previously announced connected and major transaction involving a subscription of shares and the issuance of consideration shares under a specific mandate. The termination follows the parties’...
Aceso Life Science Wins Unanimous Shareholder Backing for AGM Resolutions
Sep 16, 2026
Shareholders of Aceso Life Science Group Limited unanimously approved all ordinary resolutions at the annual general meeting held on 16 September 2026. The poll-based voting covered receipt of the audited financial statements for the year ended 31...
Aceso Life Science details fair value losses on investment portfolio
Sep 11, 2026
Aceso Life Science Group Limited has detailed the composition of its financial assets measured at fair value through other comprehensive income as at 31 March 2026, highlighting minority stakes in securities trading, property investment, and finan...
Aceso Life Science Sets 2026 AGM to Renew Mandates and Expand Share Issuance Authority
Aug 20, 2026
Aceso Life Science Group Limited, a Cayman-incorporated company listed in Hong Kong under stock code 00474, operates in the life sciences sector with a focus on health-related businesses and investment in healthcare markets. Its governance framewo...
Aceso Life Science to Resume Trading in Hong Kong After Publishing Delayed 2026 Results
Aug 13, 2026
Aceso Life Science Group Limited, a Cayman Islands-incorporated life sciences company listed in Hong Kong, operates under the oversight of a mixed board of executive, non-executive and independent non-executive directors. Its shares are traded on ...
Aceso Life Science Swings to Annual Profit on Discontinued Operations Gain
Aug 13, 2026
Aceso Life Science Group Limited, a Hong Kong-listed life sciences-focused investment and operating group, derives its results from a combination of core operations and valuation changes in investment properties and financial assets. The company&#...
Aceso Life Science Delays Dispatch of Subscription Agreement Circular Again
Aug 5, 2026
Aceso Life Science Group Limited has announced a further delay in sending a shareholder circular related to a Subscription Agreement and the planned issuance of consideration shares under a specific mandate. The circular, which will include detail...
Aceso Life Science Sets Board Date as Share Trading Remains Suspended Pending Results
Aug 3, 2026
Aceso Life Science Group Limited has scheduled a board meeting for 13 August 2026 in Hong Kong to approve and publish its audited final results for the year ended 31 March 2026 and to consider whether to recommend a final dividend. The timing and ...
Aceso Life Science Signals Profit on Subsidiary Disposal as Trading Stays Suspended
Aug 3, 2026
Aceso Life Science Group Limited has issued a positive profit alert, indicating it expects to report a profit of about HK$336 million for the year ended 31 March 2026, compared with a loss of approximately HK$1,017 million a year earlier. The turn...
Aceso Life Science Delays Dispatch of Subscription Agreement Circular to Shareholders
Jul 2, 2026
Aceso Life Science Group Limited has announced a further delay in sending a shareholder circular related to a Subscription Agreement and the proposed issue of consideration shares under a specific mandate. The circular, which will include reports ...
Aceso Life Science Delays 2026 Results, Faces Trading Suspension in Hong Kong
Jul 2, 2026
Aceso Life Science Group Limited has announced it will miss the 30 June 2026 deadline to publish its audited annual results for the year ended 31 March 2026, citing the need for additional time to collect valuation data for certain financial asset...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.